Tag Archives: Tumor Development

New Three-Part Molecule May Decrease Growth of Certain Types of Cancer Tumors

Three-Part Molecule May Decrease Growth of Certain Types of Cancer Tumors
Three-Part Molecule May Decrease Growth of Certain Types of Cancer Tumors

If one is good and two is better, is three the answer? Scientists are hoping that a new three-part molecule could be an answer regarding effective immuno oncology for breast cancer patients.

Stemming the Growth of Breast Cancer Cells

Approximately 20 to 30 percent of breast cancer cases involve over-expression of HER2, which is a growth factor that leads to aggressive multiplication of cancer cells. This acceleration often makes these types of cancer resistant to therapy, resulting in poor prognoses.

Dr. Hongyan Liu, a bioengineer at the Georgia Cancer Center, led a team that developed a chimera, or three-part molecule, to suppress the growth factors. The chimera targets HER2, HER3 and EGFR because one member of the HER “family” can compensate when another one is blocked.

Exploring the Abilities of the Three-Part Molecule

The new molecule is non-toxic, easy to manufacture and relatively cost-effective, making scientists optimistic about its value for immuno oncology. Dr. Liu and her team are currently conducting studies to determine if the chimera can treat cancer that is resistant to Herceptin, a drug that inhibits HER2.

Breast cancer is not the only form that grows due to over-expression of HER receptors. Dr. Liu is hopeful that the chimera will have future applications for lung, head and neck cancers as well.

Issels®: The Leader in Personalized Immuno Oncology Treatments

Our non-toxic immuno oncology programs have been successful in treating therapy-resistant cases of breast cancer and other forms. Contact us today to learn more about how we are carrying on the legacy of our founder, Dr. Josef M. Issels, who predicted the future of immunotherapy.

Breast Cancer Myths and Facts

Breast Cancer Information
Breast Cancer Information

One in eight American women will be diagnosed with breast cancer during her lifetime. Despite its prevalence, the chances of surviving breast cancer have improved dramatically over the past decade. But old myths still abound. Get the facts below:

Not Just for Women

Myth: Only women get breast cancer.

Fact: While breast cancer strikes women far more frequently than men, more than 2,000 men are diagnosed with breast cancer each year. By comparison, more than 200,000 women are diagnosed with breast cancer annually, about one every two minutes.

Myth: Breast cancer only strikes older women.

Fact: While it is true that breast cancer risk increases with age, breast cancer can strike women of any age. The median age for breast cancer diagnosis in the U.S. is 61 for white women and 57 for black women; but with average life expectancies in the mid-80s, cancer survivors can expect to enjoy many years of active life.

Better Survival Rates

Myth: Breast cancer is the No. 1 cause of cancer death among American women.

Fact: Lung cancer claims the lives of more U.S. women annually than breast cancer, but breast cancer is the top cancer killer of women between the ages of 40 and 59. Breast cancer kills more than 40,000 American women each year.

Myth: Few women survive breast cancer.

Fact: Your chances of surviving breast cancer have never been better. Early detection and improvements in breast cancer treatment have pushed breast cancer fatality rates down 34% since 1990. When detected early, the five-year survival rate has soared to 98%. More than 2.9 million breast cancer survivors are living and thriving in America today.

More myth-busters next time

Tumor Microenvironment Holds Key to Cancer Prevention and Treatment

Laboratory microscope
Cancer Advancements at the Tumor Microenvironment Level

The importance the tumor microenvironment plays in the development and metastasis of cancer is turning a new page in cancer research, treatment and prevention. As scientists work to unlock cancer’s genetic code, they are developing new understandings into how cancer cells communicate and the switches that turn tumor development on and off. At the core of many new discoveries is the complex relationship between cancer tumor cells and the microenvironment in which they develop.

European cancer researchers were early to recognize the importance of the tumor microenvironment. According to a 2010 Italian study, “Microenvironment components play a pivotal role in the regulation of the angiogenic switch and in cancer progression.” (Angiogenesis is the growth of new blood vessels necessary for tumor growth.) The Italian study concluded:

“The comprehension of biological and molecular mechanisms involved in the relationship between tumor cells and the microenvironment could unveil new therapeutic and preventive approaches to cancer.”

Within two years, European cancer researchers were conducting clinical applications of cancer therapies that targeted the tumor microenvironment, which a 2012 Belgian study called “an essential ingredient of cancer malignancy.” According to researchers at the Laboratory of Tumor and Development Biology at the University of Liège:

“The malignant features of cancer cells cannot be manifested without an important interplay between cancer cells and their local environment. … Thus in the clinical setting the targeting of the tumor microenvironment to encapsulate or destroy cancer cells in their local environment has become mandatory.”

One thing that distinguishes Issels Integrated Oncology from other U.S. cancer treatment programs is our use of integrative immunotherapy to specifically target the cancer tumor microenvironment.